Blood Flow Restriction Following ACLR w/Quad Autograft
Launched by UNIVERSITY OF KANSAS MEDICAL CENTER · Oct 8, 2024
Trial Information
Current as of July 24, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Specific Aim 1 will identify the overall preservation of muscle and changes in body composition after injury and throughout surgical rehabilitation in athletes undergoing ACL reconstruction. It is hypothesized that implementing BFR rehabilitation protocols following ACL reconstruction with autografts will expedite recovery and return to sport and rescue of muscle tissue at the donor site.
Specific Aim 2 will monitor muscle strength and activation following ACL reconstruction with performance of standardized assessments at intervals. It is hypothesized that BFR implementation will show grea...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient undergoing anterior cruciate ligament construction utilizing a quadriceps autograft
- • Age 14 - 40 years old
- Exclusion Criteria:
- • Comorbid conditions (i.e.: hypertension, diabetes, obesity, etc.)
- • Patient taking blood thinners or at risk of embolism
- • Revision anterior cruciate ligament construction
- • Allograft based reconstruction
- • Non-quadriceps graft
About University Of Kansas Medical Center
The University of Kansas Medical Center (KUMC) is a leading academic medical institution dedicated to advancing healthcare through innovative research, education, and clinical practice. As a prominent clinical trial sponsor, KUMC leverages its extensive expertise in diverse medical fields to conduct rigorous clinical research aimed at improving patient outcomes and developing new treatment modalities. With a commitment to ethical standards and patient safety, KUMC collaborates with multidisciplinary teams to facilitate groundbreaking studies that address significant health challenges, ultimately contributing to the advancement of medical knowledge and the enhancement of community health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kansas City, Kansas, United States
Patients applied
Trial Officials
Matthew Vopat, MD
Principal Investigator
University of Kansas Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported